一分钟看懂
这是一项关于Genitourinary Cancer的II 期研究，登记的药物或干预包括Ipilimumab；Nivolumab，当前状态为研究进行中，已停止招募。登记地点显示中国La Jolla、Atlanta、Boston、Columbus等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ipilimumab；Nivolumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of California, San Diego Moores Cancer Center · La Jolla
- Winship Cancer Institute, Emory University · Atlanta
- Beth Israel Deaconess Medical Center · Boston
- Dana-Farber Cancer Institute · Boston
- Ohio State University Comprehensive Cancer Center · Columbus
- MD Anderson Cancer Center · Houston
公开的入选条件
- * Age ≥ 18 years at the time of consent.
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 within 28 days prior to registration (Appendix A).
- * Unresectable advanced or metastatic ACC, non-urothelial bladder/upper tract cancer, non-adenocarcinoma prostate cancer, penile cancer, treatment refractory germ-cell tumor or a high grade neuroendocrine carcinoma/small cell carcinoma of any genitourinary sit
- * at this time only the bladder and neuroendocrine cohorts are open
- * Availability of Formalin-fixed, Paraffin-embedded (FFPE) archival tumor specimens, when available, and willingness of the subject to undergo mandatory fresh tumor biopsy prior to treatment initiation unless determined medically unsafe or not feasible.
- The archival specimen, when available, must contain adequate viable tumor tissue.
- The specimen may consist of a tissue block (preferred and should contain the highest grade of tumor) or at least 20 unstained serial sections. Fine-needle aspiration, brushings, cell pellet from pleural effusion, bone marrow aspirate/biopsy are not acceptable.
- A mandatory biopsy at the time of radiographic progression will be requested from patients who have an initial response to treatment and then subsequently progress as determined by RECIST version 1.1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT03333616；登记信息更新于 2026-07-23。